Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) maintains this comprehensive news hub for investors tracking developments in its clinical-stage cancer therapeutics. Our curated collection features official press releases, regulatory filings, and material event announcements related to the company’s protein phosphatase inhibitor pipeline.
This resource enables stakeholders to monitor critical updates including clinical trial progress for lead compound LB-100, financial disclosures, and strategic collaborations. All content is sourced directly from company communications and SEC filings to ensure reliability.
Key categories include Phase 1/2 trial results, intellectual property milestones, executive leadership changes, and quarterly earnings reports. Bookmark this page for timely access to investment-relevant developments in Lixte’s novel approach to enhancing chemotherapy and radiation efficacy through targeted phosphatase inhibition.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced a collaboration with the Netherlands Cancer Institute and Oncode Institute, leading to an initial joint patent application for the LB-100 combination therapy. This therapy aims to enhance anti-cancer effects in patients. The partnership focuses on identifying promising drugs to use with Lixte's LB-100 for treating various cancers and understanding the molecular mechanisms involved. CEO John S. Kovach emphasized the groundbreaking approach of stimulating pathways in cancer cells to make them more vulnerable to treatment.
Lixte Biotechnology Holdings (Nasdaq: LIXT) announced that its lead compound, LB-100, a protein phosphatase inhibitor, has shown promise in preclinical studies for enhancing the efficacy of immunotherapy in cancers like colorectal, triple-negative breast, and pancreatic cancer. Research indicates that LB-100 induces molecular changes that make tumors more susceptible to treatment. The company has initiated a clinical trial combining LB-100 with chemotherapy and an immune checkpoint blocker for patients with extensive stage small cell lung cancer, aiming to convert resistant tumors into responsive ones.
Lixte Biotechnology Holdings (Nasdaq: LIXT) announced that the National Cancer Institute has resumed patient enrollment for a study evaluating LB-100's ability to penetrate malignant brain tumors. This follows a suspension due to COVID-19. The study aims to enroll up to 20 patients, with an initial goal of obtaining pharmacologic data from 8. If successful, it could pave the way for larger trials examining LB-100's impact on treatment outcomes for glioblastoma, a challenging cancer to treat. CEO Dr. John S. Kovach emphasized the potential of LB-100 to enhance existing therapies.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) will present at the Benzinga Global Small Cap Conference on October 28, 2021. CEO John S. Kovach, M.D., will discuss the lead clinical compound, LB-100, a PP2A inhibitor, and its collaboration with the Netherlands Cancer Institute and Oncode Institute. This partnership aims to identify effective drug combinations and new targets for LB-100 in cancer treatment. Pre-clinical studies led by Professor René Bernards will utilize genome-wide functional genetic techniques to enhance treatment efficacy.
Lixte Biotechnology Holdings has announced a collaboration with the Netherlands Cancer Institute and Oncode Institute to explore drug combinations with their lead compound, LB-100. This initiative aims to enhance cancer treatment efficacy by identifying promising drug pairings and understanding the underlying molecular mechanisms. Pre-clinical studies, led by noted researcher Professor René Bernards, will utilize innovative genetic techniques to select effective drug combinations, potentially improving outcomes for patients.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced promising results from recent pre-clinical studies of its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor. The studies indicate that LB-100 may effectively reduce behavioral sensitization related to methamphetamine addiction, potentially opening avenues for future clinical trials. The company is currently focused on highly aggressive cancers, with LB-100 involved in clinical studies for conditions such as myelodysplastic syndromes and small cell lung cancer. The total addressable market for these cancer types exceeds $5 billion.
Lixte Biotechnology Holdings has announced promising results from a pre-clinical study indicating that its lead compound LB-100 enhances the efficacy of standard therapies in small cell lung cancer (SCLC). The findings underpin a recently initiated Phase 1b clinical trial at City of Hope, exploring the combination of LB-100 with carboplatin, etoposide, and atezolizumab.
LB-100 was found to increase drug uptake in tumor cells without raising toxicity, supporting its potential as a transformative treatment for aggressive cancers.
On July 22, 2021, Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced positive pre-clinical research findings regarding its lead compound, LB-100. The study revealed that LB-100, when combined with BioMarin's vosoritide, significantly enhanced bone growth in a mouse model of achondroplasia, surpassing the effects of vosoritide alone. CEO John S. Kovach highlighted LB-100's potential for treating small cell lung cancer and advanced soft tissue sarcomas, emphasizing its unique status as the only PP2A inhibitor in clinical trials. Lixte aims to demonstrate LB-100's clinical benefits across various serious diseases.
Lixte Biotechnology Holdings, Inc. announced recognition for Julio Pimentel, a doctoral student, for his research on LB-100 in triple negative breast cancer (TNBC). Pimentel was awarded the National Latino Leader Award and a scholarship to present his findings at a conference in October 2021. His research showed that LB-100 effectively inhibits TNBC cells and enhances the effectiveness of standard chemotherapy drugs like paclitaxel and cisplatin. Lixte's CEO highlighted the potential of LB-100 as a novel therapeutic approach for TNBC, which represents 15-20% of breast cancer cases in the U.S.
Lixte Biotechnology Holdings (Nasdaq: LIXT) is set to present at the MoneyShow July Virtual Expo from July 13-15, 2021. The event is accessible to the public and will feature a presentation by CEO John S. Kovach, M.D., outlining the Phase 1b/2 clinical trial for the lead compound LB-100, targeting extensive stage small cell lung cancer. This innovative trial is conducted in partnership with the City of Hope. Lixte is committed to developing effective cancer therapies and has achieved promising results with its PP2A inhibitor.
